RxDoctor Payments Data

Ritesh Shah, MD

Cardiovascular Disease · Greenville, SCNPI 1629166103

Payments from drug & device makers

$7,892in general payments, 2019–2025

Across 383 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Novartis$908
  • Amgen$823
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$709
  • Abbott$646
  • E.r. Squibb & Sons, L.L.C.$435
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,892100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,892 in reported general payments places this provider in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$187,876
Medicare patients
2,742
Services billed
3,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban497$467,609
Repatha SureclickEvolocumab189$149,343
EntrestoSacubitril/Valsartan112$99,287
JardianceEmpagliflozin81$87,591
XareltoRivaroxaban68$64,462
Praluent PenAlirocumab61$32,407
FarxigaDapagliflozin Propanediol19$14,688
Repatha SyringeEvolocumab13$11,488
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid21$7,448
Metoprolol Succinate437$4,531
Ranolazine ErRanolazine29$2,904
Flecainide Acetate39$1,947
Ezetimibe67$1,941
Atorvastatin Calcium212$1,833
Valsartan47$1,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$380$467,609497 claims
NovartisEntresto$908$99,287112 claims
Boehringer IngelheimJardiance$409$87,59181 claims
Johnson & JohnsonXarelto$344$64,46268 claims
AstraZenecaFarxiga$254$14,68819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →